Long COVID describes persistent multisystem symptoms (fatigue, dyspnoea, cognitive impairment, autonomic dysfunction) extending ≥12 weeks after acute SARS-CoV-2 infection. Proposed mechanisms include persistent viral fragments in reservoir tissues, endothelial activation with microclot formation, dysregulated immune memory (skewed Th1/Th17 responses, reduced regulatory T cells), and mitochondrial dysfunction. Placental mesenchymal stem cells and exosomes address these pathways through endothelial repair, anti-inflammatory cytokine secretion, and metabolic rescue of dysfunctional immune cells. Eleven registered clinical trials and two actively recruiting protocols evaluate MSC and exosome infusions in long-COVID cohorts, predominantly focusing on severe functional impairment or cardiopulmonary involvement.
Published phase I safety data and small phase II trials (n=20–80 per arm) document symptomatic improvement in fatigue severity, exercise tolerance, and cognitive clarity in 40–55% of infused participants over 8–12 weeks. Objective markers—circulating microclot burden, endothelial dysfunction indices, IL-6 levels—show modest reduction in responder subgroups. One multicentre registry reports durable functional improvement (60-metre walk distance, sustained exertion capacity) persisting at 6 months in 45% of treated cohorts. Blinded controlled efficacy trials remain pending.
Long-COVID MSC protocols in Sofia range €4,500–7,000 for treatment courses comprising 2–3 intravenous infusions over 6–12 weeks, alongside immunological and cardiopulmonary baseline assessment, post-treatment follow-up imaging (chest CT, echocardiography), and exercise tolerance testing. Specialised post-COVID clinics may charge facility and monitoring fees in addition to cell-preparation costs. International travel for treatment adds significantly to overall expense.
Cell therapy for Long COVID is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Long COVID programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם